Overview of CRISPR
CRISPR represents a groundbreaking tool that is revolutionizing healthcare and creating significant impact in the medical sector. CRISPR, an acronym for “Clustered Regularly Interspaced Short Palindromic Repeats,” is present in prokaryotes—microscopic, single-celled entities devoid of organelles. These sequences are part of the genomes of prokaryotes, which organize a cell’s DNA into clusters.
As a tool for editing genes, CRISPR is utilized to alter specific segments of DNA to address critical diseases. Its resourcefulness shines as it aids in protecting the body against viral assaults by integrating the invading DNA into its own genome, enabling it to identify and eliminate the virus in subsequent encounters. Notably, in contrast to other gene editing techniques, CRISPR is significantly more accurate and simpler to program, facilitating a more straightforward sequence modification process. While conventional gene-editing tools typically depend on a single protein, CRISPR uses RNA-based targeting in conjunction with the Cas9 enzyme.
The Mechanism of CRISPR
CRISPR operates by leveraging a natural defense system found in bacteria that empowers them to detect and eradicate viral threats. Upon the arrival of a virus within a bacterial cell (a prokaryote), the bacterium retains a portion of the invader’s DNA in its genome as a sort of genetic “memory.” This capability allows the bacterium to recognize and respond more adeptly to subsequent infections.
In gene editing, this mechanism is modified using two essential elements: the Cas9 enzyme, which acts as molecular scissors to sever DNA, and guide RNA, which steers Cas9 to the particular genetic segment needing alteration. After the targeted DNA is cleaved, the natural repair processes of the cell take over, permitting researchers to introduce modifications to the genetic sequence.
Unlike previous tools that relied on difficult-to-reprogram proteins, CRISPR’s RNA-directed system is more adaptable, easier to construct, and remarkably precise. This clarity and precision have allowed CRISPR to find applications in fields such as medicine, agriculture, manufacturing, and microbiology—like engineering microbes for enhanced product yields. However, as this article examines, expanding capabilities also introduce increasing ethical dilemmas, especially regarding germline editing and genetic enhancement.
First Patient in the World to Receive Personalized CRISPR Therapy
In February 2025, the first-ever personalized CRISPR therapy was administered to a baby known as KJ to assist in addressing a deficiency in Carbamoyl Phosphate Synthetase 1 (CPS1)—an enzyme that breaks down ammonia (produced during protein metabolism) into urea. A research team headed by Dr. Rebecca Ahrens-Nicklas and Dr. Kiran Musunuru at the Children’s Hospital of Philadelphia devised this treatment after years of gene editing research and collaboration with other medical professionals.
Their research concentrated on conditions impacting the urea cycle, which results in toxic ammonia accumulation, harming organs such as the brain and liver. They customized the treatment specifically for KJ’s particular type of CPS1 deficiency based on preclinical studies of related variants.
Until this point, the only CRISPR treatments authorized by the U.S. FDA have been for more prevalent conditions like sickle cell disease and beta thalassemia, affecting tens or hundreds of thousands of individuals. In KJ’s situation, his treatment was formulated within six months after his birth, focusing on his specific CPS1 variant. The team established a base editing therapy administered via lipid nanoparticles to his liver to rectify the faulty enzyme.
The treatment in February was the initial dose of three; KJ received the subsequent two doses in March and April 2025. As of his last treatment, he has not encountered any serious side effects, displays improved tolerance to dietary protein, and requires less medication to regulate ammonia levels. Although continued monitoring is necessary, Ahrens-Nicklas indicates that the outcomes thus far are encouraging.
Ethical Issues Surrounding CRISPR
Like any pioneering technology, CRISPR brings forth intricate ethical dilemmas. While its main aim is to modify somatic cells to remedy diseases, it can also affect gametes, entering the contentious territory of germline editing. Modifying DNA that will be passed on to future generations is frequently viewed as unethical—particularly when done to enhance traits instead of treating ailments.
In light of these concerns, researchers have temporarily suspended germline editing until its ethical and societal ramifications are more thoroughly understood. The unpredictability of genetic alterations, and the permanence of these changes across generations, prompts crucial inquiries about the appropriate boundaries for editing.